Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Return on Equity (2021 - 2025)

Historic Return on Equity for Xeris Biopharma Holdings (XERS) over the last 5 years, with Q3 2025 value amounting to 1.55%.

  • Xeris Biopharma Holdings' Return on Equity fell 11000.0% to 1.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.55%, marking a year-over-year decrease of 11000.0%. This contributed to the annual value of 3.01% for FY2024, which is 62600.0% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Return on Equity of 1.55% as of Q3 2025, which was down 11000.0% from 1.18% recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Return on Equity registered a high of 42.68% during Q4 2023, and its lowest value of 7.06% during Q3 2023.
  • Its 5-year average for Return on Equity is 2.6%, with a median of 0.13% in 2022.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Return on Equity skyrocketed by 445700bps in 2023, and later crashed by -407900bps in 2024.
  • Over the past 5 years, Xeris Biopharma Holdings' Return on Equity (Quarter) stood at 2.65% in 2021, then increased by 29bps to 1.89% in 2022, then surged by 2360bps to 42.68% in 2023, then crashed by -96bps to 1.89% in 2024, then decreased by -18bps to 1.55% in 2025.
  • Its Return on Equity was 1.55% in Q3 2025, compared to 1.18% in Q2 2025 and 1.39% in Q1 2025.